We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for olaparib (AstraZeneca Pty Ltd)
Active ingredients
olaparib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the maintenance treatment of patients with newly diagnosed BRCA-mutated advanced ovarian cancer.
Therapeutic area
Oncology